Business
PHBI - Pharmagreen Announces Revenue Plan For Proprietary Cannabis Tissue Culture Technology
PHBI - Pharmagreen Announces Revenue Plan For Proprietary Cannabis Tissue Culture Technology.
About this update from Pharmagreen Biotech Inc.
[{"type":"text","content":"\n\n\n\nPHBI - Pharmagreen Announces Revenue Plan For Proprietary Cannabis Tissue Culture Technology\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nPHBI - Pharmagreen Announces Revenue Plan For Proprietary Cannabis Tissue Culture Technology\nPR Newswire\nCARSON CITY, Nev., Dec. 2, 2021\n\n\n\nCARSON CITY, Nev., Dec. 2, 2021 /PRNewswire/ -- Pharmagreen Biotech, Inc., (OTC Pink: PHBI), today released a management update from CEO Peter Wojcik. The update is the first in a series of narratives breaking out the company's strategy as it begins to convert the revenue potential of its proprietary intellectual property into realized revenue. The update is included in its entirety below:\nCEO Peter Wojcik Strategic Update\nPharmagreen has reached an exciting transition stage where our proven intellectual property asset will now be leveraged to begin generating and growing revenue.\nPharmagreen has a proprietary tissue culture process that can be applied to the cannabis industry to increase the scalability of industrial grow operations at the same time preserving genetic purity and enhancing quality production.\nPharmagreen can produce starter plantlets for the CBD hemp and cannabis industries through the application of a proprietary plant tissue culture in vitro process called \"Chibafreen\". This proprietary process will produce plantlets that will be genetically identical, free of pests, and disease free with consistent and certifiable constituent properties.\nNow Pharmagreen is building an operation around its Chibafreen proprietary process to monetize the value of the asset.\nTo prepare for this transition, in May of 2019, Pharmagreen became public through a reverse merger. No reverse split was executed in conjunction with the reverse merger and there are no current plans for a reverse split.\nManagement has now initiated an OTCQB application as part of its overall, multifaceted strategy to transition the potential recurring revenue value of its Chibafreen asset into realized recurring revenue.\nThe centerpiece of our transition strategy is a 12,000 square foot state of the a...